Cellectis S.A. (CLLS) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Cellectis S.A. (CLLS) over the past year, losing 49.3% versus a loss of 64.9%. Over five years, TLSA leads with a -27.2% price change compared with -87.6% for CLLS. Tiziana Life Sciences is the larger company by market cap ($143.8 million vs $130.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | TLSA |
|---|---|---|
| Share price | $1.30 | $1.13 |
| Market cap | $130.93M | $143.80M |
| 1-day change | -2.99% | +2.73% |
| YTD return | -72.31% | -26.17% |
| 1-year return | -64.92% | -49.31% |
| 5-year return | -87.63% | -27.15% |
| EPS (TTM) | $-0.64 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $2.30 |
| 52-week low | $1.25 | $0.76 |
| Distance from 52-week high | -76.28% | -50.87% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +310.00% | +606.19% |
| Average volume | 78.59K | 717.23K |
| Shares outstanding | 72.72M | 127.26M |
| Employees | 224 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed CLLS by 15.6 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
CLLS vs TLSA FAQ
Which is bigger, Cellectis S.A. or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $143.80M compared with $130.93M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or TLSA?
TLSA returned -49.31% over the past 12 months, compared with -64.92% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.